Interaction between simvastatin and metoprolol with respect to cardiac β-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 372, Issue 2, 2005, Pages 115-124

  Nette, A Franka ^a   Abraham, Getu ^a   Ungemach, Fritz Rupert ^a   Oertel, Reinhard ^b   Kirch, Wilhelm ^b   Leineweber, Kirsten ^c   Mohr, Friedrich Wilhelm ^a   Dhein, Stefan ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYANOPINDOLOL I 125; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NORADRENALIN; RADIOLIGAND; RECEPTOR SUBTYPE; SIMVASTATIN;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD SAMPLING; BODY MASS; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG BLOOD LEVEL; FEMALE; HEART MUSCLE BIOPSY; HEART RIGHT ATRIUM; HEART SURGERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; NORADRENALIN BLOOD LEVEL; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; RECEPTOR DENSITY; RECEPTOR UPREGULATION; STANDARD; SURGICAL PATIENT; UPREGULATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL APPENDAGE; BLOOD PRESSURE; CARDIAC SURGICAL PROCEDURES; CATECHOLAMINES; CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METOPROLOL; MIDDLE AGED; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA; SIMVASTATIN; UP-REGULATION;

EID: 27144550743     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-005-0005-6     Document Type: Article

References (52)

1. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103(2):276-283
2. Amar D, Shamoon H, Frishman WH, Lazar EJ, Salama MD (1991) Effects of labetalol on perioperative stress markers and isoflurane requirements. Br J Anaesth 67(3):296-301
3. Bauersfeld W, Ratge D, Knoll E, Wisser H (1986) Determination of catecholamines in plasma by HPLC and amperometric detection. Comparison with a radioenzymatic method. J Clin Chem Clin Biochem 24(3):185-188
4. Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, Blumchen G, Claus J, Mathes P, Kappenberger L, Wieland H, Neiss A (1997) The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur Heart J 18(2):226-234
5. Bhattacharya S, Chen L, Broach JR, Powers S (1995) Ras membrane targeting is essential for glucose signaling but not for viability in yeast. Proc Natl Acad Sci USA 92(7):2984-2988
6. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J (2002) 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161(1):17-26
7. Brodde OE, Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51(4):651-690
8. Brodde OE, Daul A, Michel MC (1990) Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists. Clin Physiol Biochem 8 [Suppl 2]:11-17
9. s-coupled receptors in severely failing human hearts: no difference in dilated versus ischemic cardiomyopathy. J Cardiovasc Pharmacol 31:585-594
10. Buss JE, Mumby SM, Casey PJ, Gilman AG, Sefton BM (1987) Myristoylated α subunits of guanine nucleotide-binding regulatory proteins. Proc Natl Acad Sci U S A 84:7493-7497
11. Daaka Y, Pitcher JA, Richardson M, Stoffel RH, Robishaw JD, Lefkowitz RJ (1997) Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases. Proc Natl Acad Sci U S A 94(6):2180-2185
12. s protein α subunit after activation by the β-adrenergic receptor or cholera toxin. J Biol Chem 268:23769-23772
13. de Leeuw PW, Falke HE, Kho TL, Vandongen R, Wester A, Birkenhager WH (1977) Effects of beta-adrenergic blockade on diurnal variability of blood pressure and plasma noradrenaline levels. Acta Med Scand 202(5):389-392
14. Dimsdale JE, Hartley LH, Ruskin J, Greenblatt DJ, LaBrie R (1984) Effect of beta blockade on plasma catecholamine levels during psychological and exercise stress. Am J Cardiol 54(1):182-185
15. Dunphy JT, Greentree WK, Manahan CL, Linder ME (1998) Signalling functions of protein palmitoylation. Biochim Biophys Acta 1436(1-2):245-261
16. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V (1977) Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin Proc 52(6):379-382
17. Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, Miller RJ, Jan LY, Lefkowitz RJ, Hamm HE (1998) Molecular basis for interactions of G protein betagamma subunits with effectors. Science 280(5367):1271-1274
18. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103(7):993-999
19. Goldstein DS (1984) Plasma catecholamines in clinical studies of cardiovascular diseases. Acta Physiol Scand 527 [Suppl]:39-41
20. Goldstein JL, Brown MS (1984) Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 25(13):1450-1461
21. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J (1998) 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83(5):490-500
22. Hansson BG, Dymling JF, Manhem P, Hokfelt B (1983) Effects of penbutolol and metoprolol on blood pressure, plasma catecholamines and renin activity in hypertensive patients. Eur Heart J 4[Suppl D]:57-60
23. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7-22
24. Hjemdahl P, Freyschuss U, Juhlin-Dahnfeld A, Linde B (1984) Differentiated sympathetic activation during mental stress evoked by the stroop test. Acta Physiol Scand 527 [Suppl]:25-29
25. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL (1999) Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 95(5):229-234
26. Inglese J, Koch WJ, Caron MG, Lefkowitz RJ (1992) Isoprenylation in regulation of signal transduction by G-protein-coupled receptor kinases. Nature 359(6391):147-150
27. Jakobsen CJ, Blom L (1989) Pre-operative assessment of anxiety and measurement of arterial plasma catecholamine concentrations. The effect of oral beta-adrenergic blockade with metoprolol. Anaesthesia 44(3):249-252
28. Krauss G (2003) Biochemistry of signal transduction, 3rd edn. Wiley-VCh, Weinheim, pp 115-230
29. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282(24):2340-2346
30. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97(12):1129-1135
31. Laufs U, Marra D, Node K, Liao JK (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274(31):21926-21931
32. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G (2002) Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 53(4):911-920
33. Lindorfer MA, Sherman NE, Woodfork KA, Fletcher JE, Hunt DF, Garrison JC (1996) G protein γ-subunits with altered prenylation sequences are properly modified when expressed in Sf9 cells. J Biol Chem 271:18582-18587
34. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265-275
35. Luftjohann D, Sigit JI, Locatelli S, von Bergmann K, Schmidt HH (2001) High-dose sinivastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia. Atherosclerosis 155(1):265-266
36. Marty J, Nimier M, Rocchiccioli C, Mantz J, Luscombe F, Henzel D, Loiseau A, Desmonts JM (1990) Beta-adrenergic receptor function is acutely altered in surgical patients. Anesth Analg 71(1):1-8
37. Myung CS, Garrison JC (2000) Role of C-terminal domains of the G protein beta subunit in the activation of effectors. Proc Natl Acad Sci U S A 97(16):9311-9316
38. Oertel R, Richter K, Fauler J, Kirch W (2002) Increasing sample throughput in pharmacological studies by using dual-column liquid chromatography with tandem mass spectrometry. J Chromatogr A 948:187-192
39. Pliquett RU, Cornish KG, Peuler JD, Zucker IH (2003) Simvastatin normalizes autonomic neurol control in experimental heart failure. Circulation 107:2493-2498
40. Ridker PM, Rifai N, Pfeffer MA et al (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98:839-844
41. Ridker PM, Rifai N, Clearfield M et al (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965
42. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335(14):1001-1009
43. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301-1307
44. Stoll LL, McCormick ML, Denning GM, Weintraub NL (2004) Antioxidant effects of statins. Drugs Today (Barc) 40(12):975-990
45. Straznicky NE, Howes LG, Lam W, Louis WJ (1995) Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 75(8):582-586
46. The Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-1389
47. Thomas J, Fouad FM, Tarazi RC, Bravo EL (1983) Evaluation of plasma catecholamines in humans. Correlation of resting levels with cardiac responses to beta-blocking and sympatholytic drugs. Hypertension 5(6):858-863
48. Watson RD, Eriksson BM, Hamilton CA, Reid JL, Stallard TJ, Littler WA (1980) Effects of chronic beta-adrenoceptor antagonism on plasma catecholamines and blood pressure in hypertension. J Cardiovasc Pharmacol 2(6):725-738
49. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A (2004) Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164(13):1427-1436
50. Wolfel EE, Hiatt WR, Brammell HL, Travis V, Horwitz LD (1990) Plasma catecholamine responses to exercise after training with beta-adrenergic blockade. J Appl Physiol 68(2):586-593
51. Yasuda H, Lindorfer MA, Woodfork KA, Fletcher JE, Garrison JC (1996) Role of the prenyl group on the G protein gamma subunit in coupling trimeric G proteins to A1 adenosine receptors. J Biol Chem 271(31):18588-18595
52. Zaugg M, Tagliente T, Lucchinetti E, Jacobs E, Krol M, Bodian C, Reich DL, Silverstein JH (1999) Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery. Anesthesiology 91(6):1674-1686